BioWorld

June 28, 2002

FDA Grants Corixa's Appeal; Bexxar Will Go Before ODAC

Corixa Corp. won an appeal against an FDA decision issued earlier this year that required additional clinical trials in order to market the cancer drug Bexxar. (BioWorld Today) Read More

Exact Sciences, LabCorp Enter Molecular Diagnostics Alliance

'Smart Bomb' Nanoparticle, Killer Gene, Canny Receptor Team Up To Starve Tumor Of Blood Supply

BioDelivery Raises $10.5M In IPO To Fund Delivery Technology

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

In the clinic for June 22, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...